Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...

One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Cervical cancer is a major health issue for Indian women, primarily caused by HPV. Key symptoms include abnormal bleeding and pelvic pain. Preventive measures such as HPV vaccination, safe sex, and ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...